Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
15.40
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,087,207
Open
15.33
Bid (Size)
15.40 (2)
Ask (Size)
15.75 (10)
Prev. Close
15.40
Today's Range
15.21 - 15.60
52wk Range
14.55 - 32.59
Shares Outstanding
162,625,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
-50.10%
-50.10%
1 Month
-14.44%
-14.44%
3 Month
+1.99%
+1.99%
6 Month
-38.03%
-38.03%
1 Year
-47.49%
-47.49%
More News
Read More
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
August 07, 2024
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 07, 2024
Via
Benzinga
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
August 07, 2024
Via
Benzinga
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
July 12, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Expert Ratings For ACADIA Pharmaceuticals
June 25, 2024
Via
Benzinga
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
June 27, 2024
Via
Benzinga
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
June 18, 2024
From
Acadia Pharmaceuticals, Inc.
Via
Business Wire
3 Sorry Pharma Stocks to Sell in May While You Still Can
May 29, 2024
Via
InvestorPlace
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
May 09, 2024
Via
InvestorPlace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
April 30, 2024
Via
Benzinga
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
April 29, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
April 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
April 22, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.